AIM ImmunoTech Inc. (AIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 90K 180K 270K Q1 '10: 32K Q2 '10: 41K Q3 '10: 35K Q4 '10: 27K Q1 '11: 42K Q2 '11: 36K Q3 '11: 45K Q4 '11: 38K Q1 '12: 72K Q2 '12: 49K Q3 '12: 39K Q4 '12: 53K Q1 '13: 42K Q2 '13: 36K Q3 '13: 36K Q4 '13: 36K Q1 '14: 76K Q2 '14: 36K Q3 '14: 45K Q4 '14: 40K Q1 '15: 36K Q2 '15: 47K Q3 '15: 23K Q4 '15: 27K Q1 '16: 39K Q2 '16: 15K Q3 '16: 22K Q4 '16: 16K Q1 '17: 84K Q2 '17: 213K Q3 '17: 90K Q4 '17: 50K Q1 '18: 56K Q2 '18: 33K Q3 '18: 38K Q4 '18: 240K Q2 '19: 29K Q3 '19: 61K Q4 '19: 50K Q1 '20: 45K Q2 '20: 40K Q3 '20: 36K Q4 '20: 42K Q1 '21: 28K Q2 '21: 23K Q3 '21: 33K Q4 '21: 50K Q1 '22: 33K Q2 '22: 30K Q3 '22: 21K Q4 '22: 56K Q1 '23: 49K Q2 '23: 42K Q3 '23: 46K Q4 '23: 65K Q1 '24: 40K Q2 '24: 50K Q3 '24: 35K Q4 '24: 45K Q1 '25: 16K Q2 '25: 25K Q3 '25: 26K Q4 '25: 21K Q1 '26: 22K Q2 '26: 26K Q2 '10 Q3 '12 Q4 '14 Q1 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q1 '10: -4.1M Q2 '10: -3.8M Q3 '10: -3.7M Q4 '10: -4.9M Q1 '11: -3.6M Q2 '11: -3.2M Q3 '11: -3.6M Q4 '11: -3.9M Q1 '12: -3.7M Q2 '12: -3.6M Q3 '12: -5M Q4 '12: -8M Q1 '13: -4.6M Q2 '13: -4.7M Q3 '13: -4.5M Q4 '13: -3.4M Q1 '14: -5.1M Q2 '14: -5.1M Q3 '14: -4.3M Q4 '14: -4.6M Q1 '15: -4.9M Q2 '15: -4.9M Q3 '15: -4M Q4 '15: -2.8M Q1 '16: -3.7M Q2 '16: -2.8M Q3 '16: -3.2M Q4 '16: -4.1M Q1 '17: -3.2M Q2 '17: -2.7M Q3 '17: -2.7M Q4 '17: -2.8M Q1 '18: -2.6M Q2 '18: -3.2M Q3 '18: -3M Q4 '18: -2.7M Q1 '19: -2.9M Q2 '19: -3.2M Q3 '19: -3.2M Q4 '19: -3.1M Q1 '20: -3.3M Q2 '20: -3.3M Q3 '20: -3.4M Q4 '20: -5.2M Q1 '21: -3.7M Q2 '21: -3.7M Q3 '21: -3.9M Q4 '21: -7.4M Q1 '22: -3.2M Q2 '22: -4.7M Q3 '22: -6.5M Q4 '22: -5.6M Q1 '23: -4.3M Q2 '23: -5.5M Q3 '23: -8.2M Q4 '23: -14M Q1 '24: -5.7M Q2 '24: -3.7M Q3 '24: -4.5M Q4 '24: -5.9M Q1 '25: -3.6M Q2 '25: -2.6M Q3 '25: -2.4M Q4 '25: -3M Q1 '26: -2.2M Q2 '26: -3.5M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Net Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q1 '10: -5.4M Q2 '10: -1.4M Q3 '10: -3.8M Q4 '10: -2.5M Q1 '11: -866K Q2 '11: -2.3M Q3 '11: -2.7M Q4 '11: -3.1M Q1 '12: -2.3M Q2 '12: -3M Q3 '12: -6.6M Q4 '12: -5.5M Q1 '13: -3.6M Q2 '13: -4.3M Q3 '13: -5.1M Q4 '13: -3.2M Q1 '14: -3.8M Q2 '14: -5M Q3 '14: -4.2M Q4 '14: -4.5M Q1 '15: -3.4M Q2 '15: -4.8M Q3 '15: -3.8M Q4 '15: -3.1M Q1 '16: -2.2M Q2 '16: -1.3M Q3 '16: -2.9M Q4 '16: -1.2M Q1 '17: -2.8M Q2 '17: -2.2M Q3 '17: -1.3M Q4 '17: -2M Q1 '18: -2.7M Q2 '18: -2.4M Q3 '18: -3.1M Q4 '18: -1.6M Q1 '19: -3.4M Q2 '19: -2M Q3 '19: -2.9M Q4 '19: -1.1M Q1 '20: -3.8M Q2 '20: -3.4M Q3 '20: -3.3M Q4 '20: -3.9M Q1 '21: -3.6M Q2 '21: -5.9M Q3 '21: -3.8M Q4 '21: -5.8M Q1 '22: -3.8M Q2 '22: -4.9M Q3 '22: -6.4M Q4 '22: -4.4M Q1 '23: -3.7M Q2 '23: -4.9M Q3 '23: -7.8M Q4 '23: -12.6M Q1 '24: -5.8M Q2 '24: -1.8M Q3 '24: -3.7M Q4 '24: -6M Q1 '25: -3.7M Q2 '25: -2.8M Q3 '25: -3.3M Q4 '25: -4.2M Q1 '26: -3M Q2 '26: -3.8M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue Quarterly

0 350K 700K 1.1M Q1 '10: 140K Q2 '10: 328K Q3 '10: 181K Q4 '10: 692K Q1 '11: 193K Q2 '11: 204K Q3 '11: 217K Q4 '11: 429K Q1 '12: 280K Q2 '12: 208K Q3 '12: 988K Q4 '12: 513K Q1 '13: 191K Q2 '13: 635K Q3 '13: 252K Q4 '13: 156K Q1 '14: 323K Q2 '14: 294K Q3 '14: 306K Q4 '14: 328K Q1 '15: 372K Q2 '15: 507K Q3 '15: 353K Q4 '15: 366K Q1 '16: 268K Q2 '16: 290K Q3 '16: 272K Q4 '16: 278K Q1 '17: 270K Q2 '17: 218K Q3 '17: 399K Q4 '17: 296K Q1 '18: 208K Q2 '18: 186K Q3 '18: 208K Q4 '18: 282K Q1 '19: 231K Q2 '19: 215K Q3 '19: 230K Q4 '19: 217K Q1 '20: 204K Q2 '20: 200K Q3 '20: 204K Q4 '20: 198K Q1 '21: 237K Q2 '21: 279K Q3 '21: 157K Q4 '21: 176K Q1 '22: 77K Q2 '22: 69K Q3 '23: 30K Q4 '23: 12K Q1 '24: 8K Q2 '24: 8K Q3 '24: 8K Q4 '24: 7K Q1 '25: 10K Q2 '25: 10K Q3 '25: 68K Q4 '25: 40K Q1 '26: 4K Q2 '26: 5K Q2 '11 Q2 '13 Q2 '15 Q2 '17 Q2 '19 Q2 '21 Q2 '24 Q2 '26

Operating Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '10: -2.7M Q4 '10: -1.8M Q1 '11: -1.8M Q2 '11: -3M Q3 '11: -2.3M Q4 '11: -3M Q1 '12: -1.7M Q2 '12: -3.8M Q3 '12: -2.7M Q4 '12: -5M Q1 '13: -5.9M Q2 '13: -3.8M Q3 '13: -4M Q4 '13: -3.2M Q1 '14: -2.9M Q2 '14: -3.3M Q3 '14: -3.7M Q4 '14: -4M Q1 '15: -4.3M Q2 '15: -5M Q3 '15: -3.5M Q4 '15: -3.3M Q1 '16: -1M Q2 '16: -1.2M Q3 '16: -3M Q4 '16: -2.1M Q1 '17: -3M Q2 '17: -2.3M Q3 '17: -1.9M Q4 '17: -760K Q1 '18: -2.5M Q2 '18: -2.7M Q3 '18: -3M Q4 '18: -2.4M Q1 '19: -1.5M Q2 '19: -2.8M Q3 '19: -2.5M Q4 '19: -2.3M Q1 '20: -3.2M Q2 '20: -1.3M Q3 '20: -3M Q4 '20: -2.9M Q1 '21: -3M Q2 '21: -1.7M Q3 '21: -3.5M Q4 '21: -5.7M Q1 '22: -2.8M Q2 '22: -2.3M Q3 '22: -5M Q4 '22: -6.1M Q1 '23: -3.7M Q2 '23: -2.2M Q3 '23: -5.7M Q4 '23: -9.8M Q1 '24: -4.8M Q2 '24: -3M Q3 '24: -3.1M Q4 '24: -4M Q1 '25: -2.4M Q2 '25: -1.5M Q3 '25: -5.1M Q4 '25: -2M Q1 '26: -2.7M Q2 '26: -4.6M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '10: -2.8M Q4 '10: -2M Q1 '11: -1.9M Q2 '11: -3.3M Q3 '11: -2.7M Q4 '11: -4M Q1 '12: -3.2M Q2 '12: -5.5M Q3 '12: -4.3M Q4 '12: -5.9M Q1 '13: -6.1M Q2 '13: -4.1M Q3 '13: -4.2M Q4 '13: -3.3M Q1 '14: -3M Q2 '14: -3.5M Q3 '14: -3.8M Q4 '14: -4.2M Q1 '15: -4.3M Q2 '15: -5.2M Q3 '15: -3.5M Q4 '15: -3.3M Q3 '16: -3M Q4 '16: -2.1M Q1 '17: -3M Q2 '17: -2.3M Q3 '17: -1.9M Q4 '17: -760K Q4 '18: -2.4M Q1 '19: -1.5M Q2 '19: -2.8M Q3 '19: -2.5M Q4 '19: -2.3M Q1 '20: -3.3M Q2 '20: -1.3M Q3 '20: -3M Q4 '20: -2.9M Q3 '21: -3.5M Q4 '21: -5.8M Q4 '24: -4M Q3 '11 Q4 '12 Q1 '14 Q2 '15 Q1 '17 Q1 '19 Q2 '20 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '22: 48M Q3 '22: 48.1M Q1 '23: 48.4M Q2 '23: 48.4M Q3 '23: 48.6M Q1 '24: 49.5M Q2 '24: 528.4K Q3 '24: 576.8K Q1 '25: 703.3K Q2 '25: 759.3K Q3 '25: 2.1M Q1 '26: 4.4M Q2 '26: 17.1M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q4 '10: -0.09 Q1 '11: -0.06 Q2 '11: -0.07 Q3 '11: -0.07 Q4 '11: -0.07 Q1 '12: -0.08 Q2 '12: -0.08 Q3 '12: -0.11 Q4 '12: -0.12 Q1 '13: -0.12 Q2 '13: -0.13 Q3 '13: -0.11 Q4 '13: -0.10 Q1 '14: -0.10 Q2 '14: -0.10 Q3 '14: -0.09 Q4 '14: -1.11 Q1 '15: -1.11 Q2 '15: -1.10 Q3 '15: -1.26 Q4 '15: -0.37 Q1 '16: -0.45 Q2 '16: -0.49 Q3 '16: -0.44 Q4 '16: -0.33 Q1 '17: -0.34 Q2 '17: -0.36 Q3 '17: -0.27 Q4 '17: -0.29 Q1 '18: -0.25 Q2 '18: -2.55 Q3 '18: -5.38 Q4 '18: -6.64 Q1 '19: -9.48 Q2 '19: -8.17 Q3 '19: -6.43 Q4 '19: -2.58 Q1 '20: 0.11 Q2 '20: 1.07 Q3 '20: 2.12 Q4 '20: -0.50 Q1 '21: -0.36 Q2 '21: -0.37 Q3 '21: -0.37 Q4 '21: -0.40 Q1 '22: -0.40 Q2 '22: -0.38 Q3 '22: -0.43 Q4 '22: -0.40 Q1 '23: -0.40 Q2 '23: -0.40 Q3 '23: -0.43 Q4 '23: -0.60 Q1 '24: -0.64 Q2 '24: -3.54 Q3 '24: -9.38 Q4 '24: -19.04 Q1 '26: -3.24 Q2 '26: 0.01 Q2 '11 Q2 '13 Q2 '15 Q2 '17 Q2 '19 Q2 '21 Q2 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.